Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

Whether you're a novice or a seasoned expert, there's always more to learn and refine, ensuring that dermatology continues to advance with precision and care.

Review insights from expert faculty as they look forward to the upcoming Elevate-Derm conference.

Experts shared pearls for acne and rosacea care at Maui Derm NP+PA Fall.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

A poster presented at the EADV Congress revealed the drug's long-term efficacy in treating AD, particularly in the head and neck regions.

Connect with peers, mentors, and potential collaborators at the fully accredited Elevate Derm PA NP Conference, from November 7-10, 2024.

More than half of treatment responders maintained stable EASI ≤ 7, according to a poster from EADV.

A poster presented at EADV 2024 explored patient-reported outcomes from. the TRACE study for AD.

Shawn Kwatra, MD, presented the Incyte data at EADV 2024.

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Nearly 44.2% of patients achieved HiSCR100, indicating a complete resolution of HS symptoms by the end of the 2-year period.

Arash Mostaghimi, MD, MPH, MPA, provides insights into what clinicians need to know about deuruxolitinib for severe AA.

Key highlights of the presentations included data on delgocitinib for atopic hand eczema, and tralokinumab for head and neck atopic dermatitis.

Gooderham reviews key highlights from EADV 2024 on the ADjoin long-term extension trial for patients with moderate to severe AD.

“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.